CTIS2022-502963-39-00进行中（未招募）1 期
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension - mRNA-3745-P102
Moderna Therapeutics Inc.0 个研究点目标入组 59 人开始时间: 2023年11月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •=18 years of age at the time of informed consent. In the case of enrollment in the 12- to 17-year-old SAD or MAD Stage or the 6- to 11-year-old SAD or MAD Stage, participant and/or legally authorized representative will need to be willing and able to provide informed consent and/or assent as mandated by local regulations., GSD1a is clinically stable as evidenced by absence of hospitalization for hypoglycemia in the 4 weeks prior to Screening., Participant (and/or legally authorized representative for participants under the legal age of consent) is willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures., Diagnosis of GSD1a with confirmation by G6PC gene sequencing. Note: Genetic confirmation of GSD1a is needed by the time of study drug administration. However, all Screening procedures and other assessments may proceed based on clinical diagnosis alone., Documented history of =1 hypoglycemic event with blood glucose 60 mg/dL (<3.3 mmol/L) and symptoms of hypoglycemia in the absence of acute illness, with at least one such event in the 12 months before starting the run-in (Day -14)., Aspartate aminotransferase and alanine aminotransferase values are <2.5 times the upper limit of normal (may be repeated up to 3 times during Screening at the discretion of the Investigator)., Absolute neutrophil count =1500/mm3, a platelet count =150,000/mm3, and hemoglobin =10 g/dL., If female, must meet the following criteria: a. Not of childbearing potential (an FSH level may be measured at the discretion of the Investigator to confirm postmenopausal status), or b. If of childbearing potential, must be either not sexually active or using at least one method of highly effective contraception (failure rate <1% per year when used consistently and correctly) throughout the treatment with mRNA-3745 starting at least 28 days before the first administration of mRNA-3745 and through 52 weeks following the last administration of mRNA-3745., If female of childbearing potential, must have a negative serum pregnancy test (beta human chorionic gonadotropin [ß-hCG]) at Screening and a negative urine pregnancy test on Day -1., If male and sexually active with a female partner of childbearing potential, must agree to use a condom from Day 1 throughout the treatment with mRNA-3745 and for 52 weeks following the last dose of mRNA-3745; additionally, their female partner of childbearing potential must use at least one method of highly effective contraception (failure rate <1% per year when used consistently and correctly) throughout the male participant’s treatment with mRNA-3745 and for 52 weeks following the last dose of mRNA-3745.
排除标准
- •1. Genetically confirmed diagnosis of another inborn error of metabolism in addition to GSD1a., 18. Positive SARS-CoV-2 RT-PCR or antigen test at Screening. A positive test result does not preclude future enrollment in the study provided that the participant subsequently tests negative for SARS-CoV-2 RT-PCR or antigen. There is no limit to the number of SARS-CoV-2 RT tests that can be performed to meet eligibility., 19. History of anaphylaxis or severe hypersensitivity reactions to mRNA-based vaccines/products, requiring medical evaluation and management., 2. Previously received gene therapy for GSD1a., 20. Has any other clinically significant medical condition that in the Investigator’s opinion could interfere with the interpretation of study results, pose additional risk in administering study drug, or limit the participant’s participation in the study., 21. Requirement for continuous feeds via gastrostomy or nasogastric tubes, or IV fluids (the presence of a gastrostomy tube is not exclusionary if it is used intermittently for medications or cornstarch)., 22.Presence of an active skin condition that precludes CGM sensor placement., 3. History of solid organ transplant (including liver transplantation)., 4. History of or current diagnosis of hepatocellular carcinoma., 5. At least 1 hepatic adenoma >5 cm (± 10%) in size., 6. Diagnosis of type 1 or type 2 diabetes mellitus., 10. History of active tuberculosis requiring treatment in the past 3 years., 7. At least 1 hepatic adenoma with an increase in size of >2 cm OR a finding of >5 newly diagnosed hepatic adenomas, when compared with the last imaging (obtained with a consistent technique) performed in the preceding 2 years., 8. Positive serology for HIV (HIV 1, HIV 2), hepatitis B surface antigen, and/or hepatitis C (positive nucleic acid test for hepatitis C virus RNA) at Screening. Participants with a past or resolved hepatitis B virus infection (defined as the presence of total antibody to hepatitis B core antigen and absence of hepatitis B surface antigen) are eligible. A reactive or positive antibody test for hepatitis C virus with negative nucleic acid test for hepatitis C virus RNA is not exclusionary., 9. Long-term immunosuppression due to comorbidities and/or required pharmacological treatment, which may increase the risk of secondary opportunistic infections (eg, participants with history of autoimmune disorder[s])., 23. History of hypersensitivity to acetaminophen/paracetamol and/or ibuprofen or H1/H2-receptor blockers and changes to the premedication regimen are not possible., 11. Hematologic disorders or complement abnormalities or those on medications known to affect platelet function or coagulation pathways including newer oral anticoagulants, 12. Serum triglyceride levels >1500 mg/dL at Screening (may be repeated up to 3 times during Screening at the discretion of the Investigator)., 13. eGFR 450 ms for adult males and >470 ms for adult females, or >480 ms using Bazett’s correction for participants., 14. Clinically relevant abnormal 12-lead ECG at Screening or Day ?1 confirmed by repeat (including prolonged Fridericia corrected QT interval [defined as >450 ms for adult males and >470 ms for adult females, or >480 ms using Bazett’s correction for participants., 15. Inability to adhere to alcohol prohibition throughout the study., 16. Exclusion Criterion #16 was deleted during Protocol Amendment 6. In order to preserve subsequent numbering, this criterion number is kept
研究者
相似试验
进行中（未招募）
1 期
Phase I study to evaluate the safety of mRNA-0184 in participants with heart failureHeart failureCirculatory SystemChronic heart failureISRCTN79552451Moderna France98
进行中（未招募）
1 期
A Phase I/II clinical trial with SENS-501 in children suffering from severe to profound hearing loss due to Otoferlin (OTOF) mutationsCTIS2023-504466-28-00Sensorion12
进行中（未招募）
1 期
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age with Acid Sphingomyelinase DeficiencyEUCTR2014-003198-40-GBGenzyme Corporation20
已完成
2 期
Efficacy and host-pathogen response of heat treatment in patients with Buruli ulcer (BU) using a Phase Change Material (PCM) deviceISRCTN72102977niversity Hospital Heidelberg (Universitätsklinikum Heidelberg) (Germany)100
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Multiple Combination Therapies in Participants with Chronic Hepatitis BChronic Hepatitis B (CHB)MedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-002086-35-GBF. Hoffmann-La Roche Ltd90